Intellia Therapeutics, Inc.

Intellia Therapeutics is a biopharmaceutical company that develops treatments utilizing CRISPR gene editing, lipid nanoparticles, and oligonucleotide technologies to address severe genetic diseases. Its lead investigational product candidates are lonvoguran ziclumeran, designed for hereditary angioedema, and nexiguran ziclumeran, developed for transthyretin amyloidosis. Both therapies are designed as one-time intravenous infusions. The company also develops preclinical and clinical-stage programs in cellular therapies, including universal CAR-T cell treatments. Its therapies target individuals diagnosed with rare and life-threatening conditions, while the business works alongside healthcare prescribers, clinical institutions, and pharmaceutical collaboration partners such as Regeneron.

Operationally, the company conducts international Phase 3 clinical trials, including studies that have enrolled dozens to hundreds of patients across multiple trial sites. Its development activities and commercial infrastructure focus primarily on the United States, alongside regulatory engagements in the European Union and the United Kingdom. The provided text does not identify the location of the company’s corporate headquarters.

Summary of the business section of Intellia Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 13, 2026, we had 377 full-time employees, 263 of whom were primarily engaged in research and development activities and 106 of whom have an M.D.”